EU approves Novo Nordisk hemophilia treatment

Published on 21/11/2026 • By Endah Wijaya • Risk Factors
EU approves Novo Nordisk hemophilia treatment - hemophilia treatment
The European Commission granted clearance in November 2026.

The European Commission has granted Novo Nordisk clearance for FREHEMGO® (denecimig)—a medication designed to minimize or prevent bleeding incidents in both adult and pediatric patients diagnosed with hemophilia A. This regulatory green light, disclosed in November 2026, applies across Denmark and all EU nations.

The decision stems from a favorable recommendation issued in September 2026 by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). FREHEMGO functions as an advanced bispecific antibody that replicates the effects of activated factor VIII (FVIIIa), a critical protein in the blood-clotting process.

Delivered via subcutaneous injection, the therapy provides three flexible dosing regimens: weekly, biweekly, or monthly. Patients can self-administer it using a disposable pre-filled pen, enabling customization of their treatment schedule to align with personal preferences.

Maria Elisa Mancuso, a World Federation of Hemophilia Board Director and hematology specialist at Milan’s IRCCS Humanitas Research Hospital, emphasized that expanded treatment choices empower both patients and clinicians to tailor therapy to individual lifestyles and daily commitments.

The European approval is based on data from Novo’s FRONTIER clinical trials. The FRONTIER2 study demonstrated that denecimig substantially lowered annualized bleeding rates compared to existing prophylaxis and on-demand clotting factor treatments among hemophilia A patients.

Findings from FRONTIER3, which included children under 12, mirrored the treatment’s effectiveness seen in older adolescents and adults. Across all trials, participants exhibited remarkably low average annual bleeding rates, with many experiencing no bleeding episodes requiring treatment.

Martin Holst Lange, Novo Nordisk’s Chief Scientific Officer and Executive Vice President of R&D, stated that the approval validates the FRONTIER program’s results, confirming the drug’s ability to protect against bleeding across diverse age groups and inhibitor statuses.

FREHEMGO has already secured marketing approval in Saudi Arabia, while regulatory reviews, including one by the U.S. FDA, are ongoing. The European nod strengthens Novo Nordisk’s footprint in hemophilia therapies, where convenience and extended dosing intervals are key priorities.

The company is now advancing preparations to ensure hemophilia A patients can access this innovative treatment option as swiftly as possible.

You may also like

Leave a Comment

Your email address will not be published. Required fields are marked *